ORPHA:485421
MFF-related encephalopathy due to mitochondrial and peroxisomal fission defect
Also known as: Leigh-like basal ganglia disease-optic atrophy-peripheral neuropathy syndrome · Leigh-like encephalopathy-optic atrophy-peripheral neuropathy syndrome
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
21
37.8th percentile
Trials
0
Interventional, condition-specific
Researchers
137
Distinct authors in sample
Gene link
MFF
Definitive
Readiness
2/6
Stages with a signal
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0014905
- OMIM:617086
- UMLS:C4310726
Additional Mondo synonyms (4)
EMPF2 · MFF-associated encephalopathy due to peroxisomal and mitochondrial fission defect · encephalopathy due to defective mitochondrial and peroxisomal fission 2 · encephalopathy due to defective mitochondrial and peroxisomal fission type 2
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — MFF
- LiteraturePresent
21 matched papers (21 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (MFF).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
21
21 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
21 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
21 in the last 10 years · high confidence · 37.8th percentile (publications denominator)
Phrase hits: 21 · MeSH hits: 0
Who's working on it?
137
Distinct author names in 21 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01El-Hattab AW2 papers · 2022
College of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates.
Papers in Europe PMC - 02Salah A2 papers · 2022
Pediatrics Department, University Hospital Sharjah, Sharjah 72772, United Arab Emirates.
Papers in Europe PMC - 03Ahmad I1 paper · 2020
Genomics and Molecular Medicine, CSIR-Institute of Genomics and Integrative Biology, Delhi, India.
Papers in Europe PMC - 04Al Ojaimi M1 paper · 2022
College of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates.
Papers in Europe PMC - 05Ali S1 paper · 2018
Department of Life Sciences, New York Institute of Technology, Northern Boulevard, Old Westbury, NY 11568, USA. sali51@nyit.edu.
Papers in Europe PMC - 06Almannai M1 paper · 2022
Genetics and Precision Medicine Department, King Abdullah Specialized Children Hospital, Riyadh P.O. Box 22490, Saudi Arabia.
Papers in Europe PMC - 07Ando M1 paper · 2022
Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima City, Kagoshima, 890-8520, Japan.
Papers in Europe PMC - 08Baker MJ1 paper · 2022
Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3052, Australia.
Papers in Europe PMC - 09Balazovskaia S1 paper · 2025
Saint Petersburg Institute of Bioregulation and Gerontology, Saint-Petersburg 197110, Russia.
Papers in Europe PMC - 10Bartnik E1 paper · 2018
Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, Pawinskiego 5a, 02-106, Warsaw, Poland.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
Broader category encephalopathy due to mitochondrial and peroxisomal fission defect also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Broader category: encephalopathy due to mitochondrial and peroxisomal fission defect
0
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Parent-category matching found a broader label but no interventional trials under it. How we count trials.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"MFF-related encephalopathy due to mitochondrial and peroxisomal fission defect" OR "Leigh-like basal ganglia disease-optic atrophy-peripheral neuropathy syndrome" OR "Leigh-like encephalopathy-optic atrophy-peripheral neuropathy syndrome" OR "EMPF2" OR "MFF-associated encephalopathy due to peroxisomal and mitochondrial fission defect" OR "encephalopathy due to defective mitochondrial and peroxisomal fission 2" OR "encephalopathy due to defective mitochondrial and peroxisomal fission type 2"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"MFF-related encephalopathy due to mitochondrial and peroxisomal fission defect" OR "Leigh-like basal ganglia disease-optic atrophy-peripheral neuropathy syndrome" OR "Leigh-like encephalopathy-optic atrophy-peripheral neuropathy syndrome" OR "EMPF2" OR "MFF-associated encephalopathy due to peroxisomal and mitochondrial fission defect" OR "encephalopathy due to defective mitochondrial and peroxisomal fission 2" OR "encephalopathy due to defective mitochondrial and peroxisomal fission type 2" OR "MFF" OR "Mendelian encephalopathy" OR "mitochondrial oxidative phosphorylation disorder" OR "disorder of defective peroxisomal and mitochondrial fission"
Recall-expansion terms: MFF, Mendelian encephalopathy, mitochondrial oxidative phosphorylation disorder, disorder of defective peroxisomal and mitochondrial fission
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"encephalopathy due to mitochondrial and peroxisomal fission defect"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T17:20:30.970Z